-
1 Comment
Physiomics Plc is currently in a long term downtrend where the price is trading 8.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.1.
Physiomics Plc's total revenue sank by 0.0% to $172K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-41K since the same quarter in the previous year.
Finally, its free cash flow grew by 96.6% to $28K since the same quarter in the previous year.
Based on the above factors, Physiomics Plc gets an overall score of 2/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
ISIN | GB00BDR6W943 |
Exchange | LSE |
CurrencyCode | GBP |
Market Cap | 1M |
---|---|
PE Ratio | None |
Beta | 1.59 |
Target Price | 0.2 |
Dividend Yield | None |
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. The company was incorporated in 2001 and is based in Oxford, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PYC.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025